Cellectar Biosciences
CLRB | NASDAQ
$1.01
-$0.13 (-11.40%)
At close: Nov 16, 2026, 4:00 PM ET
$1.01
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-11.40%
(1D)No price chart data available for 1D timeframe.
Rating
37.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #604/1021 (Top 59%)
Key Statistics
Market Data
Market Cap $17.64M
1D Range
1.00 1.13
52W Range
1.00 4.04
Valuation (TTM)
PE -0.28
PB 0.79
EV/EBITDA 0.21
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $11.00
Cash Flow
FCF Yield -139.6%
SBC Adj. FCF Yield -145.0%
SBC Impact -3.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 111.7% |
56.8%
FCF 3Y | 5Y 32.6% |
-1.0%
Returns
ROA -86.9%
ROE -154.5%
ROIC -111.8%
Financial Health
Net Cash
$24.58M
Current Ratio 4.44
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosi...
Sector Healthcare
Industry Biotechnology
Employees 11
IPO Date Nov 10, 2005
Website www.cellectar.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$11.00
Upside
+989.11%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CLRB